文献速递白血病

儿童急性淋巴细胞白血病结局的基因组决定因素

Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2024-08-09

该研究对儿童标准风险或高危B-ALL且细胞遗传学特征良好者进行基因组和转录组测序,采用病例对照设计分析439例复发与1057例持续完全缓解至少5年的患者,发现基因组亚型、非整倍体模式和继发性基因组改变决定复发风险,需综合基因组分析以优化风险分层。

要点

  • PAX5改变型ALL复发率约50%,OR 3.31(95%CI 2.17-5.03),P=3.18×10⁻⁸。
  • 在高超二倍体ALL中,10号染色体增益伴7号染色体二体与良好结局相关(OR 0.27)。
  • 10号和17号染色体二体伴6号染色体增益与复发相关(OR 7.16),验证队列OR 21.32。

核心结论

  • 遗传亚型、非整倍体模式和继发性基因组改变决定儿童ALL的复发风险。
  • 综合基因组分析是优化风险分层的必要条件。

研究设计与样本

  • 病例对照研究,对儿童肿瘤协作组试验中入组的标准风险ALL(n=1,381)或具有良好细胞遗传学特征的高危B-ALL(n=115)患儿进行诊断和缓解样本的基因组和转录组测序。
  • 分析439例复发患者和1,057例持续完全缓解至少5年的患者。

主要发现

  • 基因组亚型与复发相关,PAX5改变型ALL中约50%发生复发(OR 3.31,95%CI 2.17-5.03,P=3.18×10⁻⁸)。
  • 在高超二倍体ALL中,10号染色体增益伴7号染色体二体与良好结局相关(OR 0.27,95%CI 0.17-0.42,P=8.02×10⁻¹⁰;圣犹达儿童研究医院验证队列:OR 0.22,95%CI 0.05-0.80,P=0.009)。
  • 10号和17号染色体二体伴6号染色体增益与复发相关(OR 7.16,95%CI 2.63-21.51,P=2.19×10⁻⁵;验证队列:OR 21.32,95%CI 3.62-119.30,P=0.0004)。
  • 基因组改变以亚型依赖的方式与复发相关,包括ETV6::RUNX1 ALL中的INO80改变、高超二倍体ALL中的IKZF1和CREBBP改变以及BCR::ABL1样ALL中的FHIT改变。
  • 基因组改变还与微小残留病的存在相关,包括高超二倍体ALL中的NRAS和CREBBP改变。

关键数值与推荐

  • PAX5改变型ALL复发OR 3.31(95%CI 2.17-5.03),P=3.18×10⁻⁸。
  • 高超二倍体ALL中10号染色体增益伴7号染色体二体:OR 0.27(95%CI 0.17-0.42),P=8.02×10⁻¹⁰;验证队列OR 0.22(95%CI 0.05-0.80),P=0.009。
  • 10号和17号染色体二体伴6号染色体增益:OR 7.16(95%CI 2.63-21.51),P=2.19×10⁻⁵;验证队列OR 21.32(95%CI 3.62-119.30),P=0.0004。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATERIALS AND METHODS: To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B-ALL with favorable cytogenetic features (n = 115) enrolled on Children's Oncology Group trials. We used a case-control study design analyzing 439 patients who relapsed and 1,057 who remained in complete remission for at least 5 years. RESULTS: Genomic subtype was associated with relapse, which occurred in approximately 50% of cases of PAX5-altered ALL (odds ratio [OR], 3.31 [95% CI, 2.17 to 5.03]; P = 3.18 × 10-8). Within high-hyperdiploid ALL, gain of chromosome 10 with disomy of chromosome 7 was associated with favorable outcome (OR, 0.27 [95% CI, 0.17 to 0.42]; P = 8.02 × 10-10; St Jude Children's Research Hospital validation cohort: OR, 0.22 [95% CI, 0.05 to 0.80]; P = .009), and disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16 [95% CI, 2.63 to 21.51]; P = 2.19 × 10-5; validation cohort: OR, 21.32 [95% CI, 3.62 to 119.30]; P = .0004). Genomic alterations were associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6::RUNX1 ALL, IKZF1, and CREBBP in high-hyperdiploid ALL and FHIT in BCR::ABL1-like ALL. Genomic alterations were also associated with the presence of minimal residual disease, including NRAS and CREBBP in high-hyperdiploid ALL. CONCLUSION: Genetic subtype, patterns of aneuploidy, and secondary genomic alterations determine risk of relapse in childhood ALL. Comprehensive genomic analysis is required for optimal risk stratification.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chang TC, Chen W, Qu C, et al. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024. PMID: 39121442. doi:10.1200/JCO.23.02238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。